Jennison Associates’s BeOne Medicines Ltd ONC Stock Holding History

Jennison Associates’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.7M	Sell	100,698 -53,767	-35%	-$15.8M	0.02%	295
2026 Q1	$45.9M	Buy	154,465 +78,027	+102%	+$25.3M	0.03%	232
2025 Q4	$23.2M	Buy	76,438 +2,840	+4%	+$930K	0.01%	318
2025 Q3	$25.1M	Buy	+73,598	New	+$22.3M	0.01%	310
2021 Q3	–	Sell	-27,230	Closed	-$9.35M	–	740
2021 Q2	$9.35M	Buy	27,230 +7,131	+35%	+$2.36M	0.01%	466
2021 Q1	$7M	Buy	20,099 +12,708	+172%	+$4.21M	0.01%	448
2020 Q4	$1.91M	Buy	7,391 +2,041	+38%	+$562K	﹤0.01%	522
2020 Q3	$1.53M	Buy	5,350 +492	+10%	+$116K	﹤0.01%	514
2020 Q2	$915K	Buy	4,858 +2,617	+117%	+$426K	﹤0.01%	531
2020 Q1	$276K	Buy	2,241 +35	+2%	+$5.47K	﹤0.01%	610
2019 Q4	$366K	Buy	+2,206	New	+$367K	﹤0.01%	610
2019 Q2	–	Sell	-4,513	Closed	-$596K	–	679
2019 Q1	$596K	Hold	4,513	–	–	﹤0.01%	606
2018 Q4	$633K	Buy	4,513 +86	+2%	+$11.4K	﹤0.01%	576
2018 Q3	$762K	Buy	4,427 +43	+1%	+$7.23K	﹤0.01%	576
2018 Q2	$674K	Buy	+4,384	New	+$782K	﹤0.01%	594

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jennison Associates's ONC Position: Q2 2026 in Review

Jennison Associates reduced its BeOne Medicines Ltd (ONC) stake by 35% in Q2 2026, selling an estimated $15.8M and leaving 100,698 shares worth $28.7M. The position accounts for 0.02% of the portfolio, ranked #295.

Jennison Associates first reported a position in ONC in Q2 2018 and has held it in 15 quarters since. The position peaked at $45.9M in Q1 2026. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Jennison Associates held 100,698 shares of BeOne Medicines Ltd worth $28.7M as of Q2 2026.
Jennison Associates sold 53,767 BeOne Medicines Ltd shares in Q2 2026, an estimated $15.8M.
BeOne Medicines Ltd made up 0.02% of Jennison Associates's portfolio in Q2 2026, its #295 holding.
Jennison Associates first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 15 quarters since.
Jennison Associates's BeOne Medicines Ltd position peaked at $45.9M in Q1 2026.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.